Christopher I. Amos

ORCID: 0000-0002-8540-7023
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Genetic Associations and Epidemiology
  • RNA modifications and cancer
  • Epigenetics and DNA Methylation
  • BRCA gene mutations in cancer
  • Genetic factors in colorectal cancer
  • Cancer-related molecular mechanisms research
  • Lung Cancer Treatments and Mutations
  • Nutrition, Genetics, and Disease
  • Cancer Genomics and Diagnostics
  • Bioinformatics and Genomic Networks
  • Genetic Mapping and Diversity in Plants and Animals
  • Genomic variations and chromosomal abnormalities
  • Gene expression and cancer classification
  • Occupational and environmental lung diseases
  • Cancer Immunotherapy and Biomarkers
  • Cutaneous Melanoma Detection and Management
  • Genetic and phenotypic traits in livestock
  • Cancer-related Molecular Pathways
  • Pleural and Pulmonary Diseases
  • Liver Disease Diagnosis and Treatment
  • Ferroptosis and cancer prognosis
  • Colorectal Cancer Screening and Detection
  • Radiomics and Machine Learning in Medical Imaging
  • Genomics and Rare Diseases
  • Molecular Biology Techniques and Applications

Houston Institute for Clinical Research
2017-2025

Baylor College of Medicine
2015-2025

Baylor School
2019-2024

The University of Texas MD Anderson Cancer Center
2009-2023

Dartmouth College
2014-2023

Children's Cancer Center
2011-2023

Royal Prince Alfred Hospital
2023

Sydney Local Health District
2023

The University of Texas Health Science Center at Houston
1996-2022

Dartmouth Hospital
2013-2022

Rheumatoid arthritis is a chronic inflammatory disease with substantial genetic component. Susceptibility to has been linked region on chromosome 2q.We tested single-nucleotide polymorphisms (SNPs) in and around 13 candidate genes within the previously 2q for association rheumatoid arthritis. We then performed fine mapping of STAT1-STAT4 total 1620 case patients established 2635 controls, all from North America. Implicated SNPs were further an independent case-control series 1529 early 881...

10.1056/nejmoa073003 article EN New England Journal of Medicine 2007-09-05

Background Assessing the relationship between lung cancer and metabolic conditions is challenging because of confounding effect tobacco. Mendelian randomization (MR), or use genetic instrumental variables to assess causality, may help identify drivers cancer. Methods findings We identified instruments for potential risk factors evaluated these in relation using 29,266 cases (including 11,273 adenocarcinomas, 7,426 squamous cell 2,664 small cases) 56,450 controls. The MR analysis suggested a...

10.1371/journal.pone.0177875 article EN public-domain PLoS ONE 2017-06-08

Mutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. We determined whether tumor pathologic features clinical differ patients with without BRCA mutations.Tumor characteristics were examined 491 women cancer who underwent genetic testing for mutations between 1997 2006. A retrospective review medical records was conducted to determine including ethnicity, age stage at diagnosis, parity, number full-term pregnancies, use oral contraceptives hormone...

10.1200/jco.2008.16.6231 article EN Journal of Clinical Oncology 2008-09-08

Primary biliary cirrhosis is a chronic granulomatous cholangitis, characteristically associated with antimitochondrial antibodies. Twin and family aggregation data suggest that there significant genetic predisposition to primary cirrhosis, but the susceptibility loci are unknown.To identify conferring risk for we carried out genomewide association analysis in which DNA samples from 2072 Canadian U.S. subjects (536 patients 1536 controls) were genotyped more than 300,000 single-nucleotide...

10.1056/nejmoa0810440 article EN New England Journal of Medicine 2009-05-21
Kevin B. Jacobs Meredith Yeager Weiyin Zhou Sholom Wacholder Zhaoming Wang and 95 more Benjamín Rodríguez‐Santiago Amy Hutchinson Xiang Deng Chenwei Liu Marie-Josèphe Horner Michael Cullen Caroline G. Epstein Laurie Burdett Michael Dean Nilanjan Chatterjee Joshua N. Sampson Charles C. Chung Joseph Kovaks Susan M. Gapstur Victoria L. Stevens Lauren T. Teras Mia M. Gaudet Demetrius Albanes Stephanie J. Weinstein Jarmo Virtamo Philip R. Taylor Neal D. Freedman Christian C. Abnet Alisa M. Goldstein Nan Hu Kai Yu Jian‐Min Yuan Linda M. Liao Ti Ding You‐Lin Qiao Yu-Tang Gao Woon‐Puay Koh Yong-Bing Xiang Ze-Zhong Tang Jin‐Hu Fan Melinda C. Aldrich Christopher I. Amos William J. Blot Cathryn H. Bock Elizabeth M. Gillanders Curtis C. Harris Christopher A. Haiman Brian E. Henderson Laurence N. Kolonel Loı̈c Le Marchand Lorna H. McNeill Benjamin A. Rybicki Ann G. Schwartz Lisa B. Signorello Margaret R. Spitz John K. Wiencke Margaret Wrensch Xifeng Wu Krista A. Zanetti Regina G. Ziegler Jonine D. Figueroa Montserrat García‐Closas Núria Malats Gaëlle Marenne Ludmila Prokunina‐Olsson Dalsu Baris Molly Schwenn Alison Johnson Maria Teresa Landi Lynn R. Goldin Dario Consonni Pier Alberto Bertazzi Melissa Rotunno Preetha Rajaraman Ulrika Andersson Laura E. Beane Freeman Christine D. Berg Julie E. Buring Mary Ann Butler Tania Carreón Maria Feychting Anders Ahlbom J. Michael Gaziano Graham G. Giles Göran Hallmans Susan E. Hankinson Patricia Hartge Roger Henriksson Peter D. Inskip Christoffer Johansen Annelie Landgren Roberta McKean‐Cowdin Dominique S. Michaud Beatrice S. Melin Ulrike Peters Avima M. Ruder Howard D. Sesso Gianluca Severi Xiao‐Ou Shu Kala Visvanathan

10.1038/ng.2270 article EN Nature Genetics 2012-05-06

10.1038/ng.3002 article EN Nature Genetics 2014-06-01

BackgroundReliable risk prediction tools for estimating individual probability of lung cancer have important public health implications. We constructed and validated a comprehensive clinical tool by smoking status.

10.1093/jnci/djk153 article EN JNCI Journal of the National Cancer Institute 2007-04-30
Roger L. Milne Karoline Kuchenbaecker Kyriaki Michailidou Jonathan Beesley Siddhartha Kar and 95 more Sara Lindström Shirley Hui Audrey Lemaçon Penny Soucy Joe Dennis Xia Jiang Asha Rostamianfar Hilary K. Finucane Manjeet K. Bolla Lesley McGuffog Qin Wang Cora M. Aalfs Marcia Adams Julian Adlard Simona Agata Shahana Ahmed Habibul Ahsan Kristiina Aittomäki Fares Al‐Ejeh Jamie Allen Christine B. Ambrosone Christopher I. Amos Irene L. Andrulis Hoda Anton‐Culver Natalia Antonenkova Volker Arndt Norbert Arnold Kristan J. Aronson Bernd Auber Paul L. Auer Margreet G.E.M. Ausems Jacopo Azzollini François Bacot Judith Balmañà Monica Barile Laure Barjhoux Rósa B. Barkardóttir Myrto Barrdahl Daniel R. Barnes Daniel Barrowdale Caroline Baynes Matthias W. Beckmann Javier Benı́tez Marina Bermisheva Leslie Bernstein Yves‐Jean Bignon Kathleen R. Blazer Marinus J. Blok Carl Blomqvist William J. Blot Kristie Bobolis Bram Boeckx Natalia Bogdanova Anders Bojesen Stig E. Bojesen Bernardo Bonanni Anne‐Lise Børresen‐Dale Anikó Bozsik Angela R. Bradbury Judith S. Brand Hiltrud Brauch Hermann Brenner Brigitte Bressac–de Paillerets Carole Brewer Louise A. Brinton Per Broberg Angela Brooks‐Wilson Joan Brunet Thomas Brüning Barbara Burwinkel Saundra S. Buys Jinyoung Byun Qiuyin Cai Trinidad Caldés Maria A. Caligo Ian Campbell Federico Canzian Olivier Caron Ángel Carracedo Brian D. Carter Jose E. Castelao Laurent Castéra Virginie Caux‐Moncoutier Salina Chan Jenny Chang‐Claude Stephen J. Chanock Xiaohong Chen Ting‐Yuan David Cheng Jocelyne Chiquette Hans Christiansen Kathleen Claes Christine L. Clarke Thomas Conner Don Conroy Jackie Cook

10.1038/ng.3785 article EN Nature Genetics 2017-10-23

An accurate evaluation of the penetrance BRCA1 and BRCA2 mutations is essential to identification clinical management families at high risk breast ovarian cancer. Existing studies have focused on Ashkenazi Jews (AJ) or from outside United States. In this article, we consider US population using largest US-based cohort date both AJ non-AJ families.We collected 676 1,272 other ethnicities through Cancer Genetics Network. Two hundred eighty-two were based, whereas remainder was counseling...

10.1200/jco.2005.03.6772 article EN Journal of Clinical Oncology 2006-02-16
Coming Soon ...